April 14, 2011
William P. Bro, Kidney Cancer Association
At the Kidney Cancer foundation we’re constantly seeking new ways to ensure those with cancer have access to the best medical data and medicines possible. For the past 20 years, we have served as a source of support and information for individuals and their loved ones affected by kidney cancer and related illnesses. Read more
April 14, 2011
William P. Bro, Kidney Cancer Association
At the Kidney Cancer foundation we’re constantly seeking new ways to ensure those with cancer have access to the best medical data and medicines possible. For the past 20 years, we have served as a source of support and information for individuals and their loved ones affected by kidney cancer and related illnesses. Read more
April 14, 2011
Tom Blackwell, National Post
A growing tide of high-priced specialty medicines for arthritis, cancer and other diseases is set to put unprecedented pressure on workplace drug plans, likely forcing strict limits on what they cover, higher employee premiums and even an end to some plans altogether, experts are warning. Read more
February 16, 2011
Obtaining approval of new drugs can take as much money as $1 billion by the time research, manufacturing, safety and clinical trials have concluded. The pharmaceutical company patents the drug as soon as it is made, usually very early in the process of drug development. The patent protects that drug from being copied by anyone else for 20 years, but it can take well more than half that time to get the drug on the market. Read More
February 16, 2011
Obtaining approval of new drugs can take as much money as $1 billion by the time research, manufacturing, safety and clinical trials have concluded. The pharmaceutical company patents the drug as soon as it is made, usually very early in the process of drug development. The patent protects that drug from being copied by anyone else for 20 years, but it can take well more than half that time to get the drug on the market. Read More
February 16, 2011
A U.S. government proposal to bring cheaper generic drugs to the market more quickly and help curb health-care costs has triggered criticism from the European pharmaceutical sector. Many drug makers fear that cutting the patent protection for biologic drugs to seven years from 12 years will upend their business models and curtail their ability to develop new drugs and generate profits. Read More
February 14, 2011
Big pharmaceutical companies could face increased competition from generic drugmakers under two proposals put forth by the Obama administration on Monday despite earlier savings extracted from drugmakers as part of last year’s healthcare law. Read More
February 14, 2011
Big pharmaceutical companies could face increased competition from generic drugmakers under two proposals put forth by the Obama administration on Monday despite earlier savings extracted from drugmakers as part of last year’s healthcare law. Read More
February 14, 2011
The Obama Administration’s fiscal 2012 budget document includes a call to reduce innovator biologics exclusivity from the 12 years just enacted as part of the health care reform law to 7 years, a number more in line with the position supported by advocates on the generic/drug/purchaser/consumer side of the debate. Read More
February 14, 2011
The Obama Administration’s fiscal 2012 budget document includes a call to reduce innovator biologics exclusivity from the 12 years just enacted as part of the health care reform law to 7 years, a number more in line with the position supported by advocates on the generic/drug/purchaser/consumer side of the debate. Read More
